Results 241 to 250 of about 1,301,601 (302)

Beta adrenergic blocking drugs

Pharmacology & Therapeutics, 1980
Although the beta-adrenoceptor blocking drugs were initially used in the treatment of angina pectoris, arrhythmias and phaeochromocytoma, other uses have been found which were not originally predicted from an understanding of the pharmacology of these agents.
B N, Prichard, C W, Owens
openaire   +2 more sources

Neuromuscular blocking drugs

Canadian Anaesthetists’ Society Journal, 1983
Muscle relaxants of this type act at the neuromuscular junction, interfering with the transmission of impulses from motor nerves to skeletal muscles, as distinct from the centrally acting muscle relaxants such as mephenesin, meprobamate, diazepam, and baclofen.
openaire   +3 more sources

Calcium Channel-Blocking Drugs

Archives of Pediatrics & Adolescent Medicine, 1986
Sir .—We read with great interest the article that appeared in thefrom research to relevancesection of a recent issue of AJDC . 1 In this article, Drs Cho and Pruitt very nicely review the applications of calcium channel-blocking drugs in clinical practice, with emphasis on their use in the pediatric age group. We would like to point out, however, the
W C, Miller-Hance, J T, Stull
openaire   +2 more sources

Beta-Adrenergic Blocking Drugs

Annual Review of Medicine, 1985
There are currently six beta-adrenoceptor blocking drugs on the market. Although all the drugs competitively interact with the beta-adrenergic receptors, their pharmacokinetics and ancillary properties distinguish them from one another. By understanding these differences, the various beta-adrenoceptor drugs can be rationally used to a therapeutic ...
J G, Gerber, A S, Nies
openaire   +2 more sources

Drug and Drug Candidate Building Block Analysis

Journal of Chemical Information and Modeling, 2009
Drug likeness analysis is widely used in modern drug design. However, most drug likeness filters, represented by Lipinski's "Rule of 5", are based on drugs' simple structural features and some physiochemical properties. In this study, we conducted thorough structural analyses for two drug datasets.
Junmei, Wang, Tingjun, Hou
openaire   +2 more sources

New Neuromuscular Blocking Drugs

New England Journal of Medicine, 1995
The new nondepolarizing neuromuscular blocking drugs have specific advantages over succinylcholine. Rocuronium has an onset of action that is almost as rapid as that of succinylcholine and may be useful in patients with residual gastric contents. This drug may replace vecuronium, since the two agents are otherwise similar.
openaire   +2 more sources

Ventilation and neuromuscular blocking drugs

Acta Anaesthesiologica Scandinavica, 1994
Ventilatory failure after administration of neuromuscular blocking agents is an important factor in anaesthesia‐related perioperative morbidity and mortality. Improved knowledge and new monitoring methods may avoid ventilatory failure caused by incomplete recovery of neuromuscular function in the postoperative period.
openaire   +2 more sources

Beta adrenoceptor blocking drugs

1989
The variation in properties of beta adrenoceptor blocking drugs can be used as a basis for classification. There are those which are non-selective, those which have a selective action on the beta1receptors, and then those drugs which in addition possess vasodilator or alpha receptor blocking properties.
openaire   +2 more sources

Withdrawal of beta-blocking drugs

American Heart Journal, 1982
Our early observations indicated that when treatment was changed from propranolol to placebo, anginal patients experienced a higher incidence of chest pain during the first week of placebo treatment compared to the second week. Since then, there have been several reports of myocardial infarction and sudden death occurring when propranolol therapy has ...
R J, Walden, J, Hernandez, Y, Yu, A, Al-Khader, B N, Prichard   +4 more
openaire   +2 more sources